CITY OF MEXICO, October 27, 2021 / PRNewswire / – Genomma Lab Internacional, SAB de CV. (BMV: LAB B) (“Genomma Lab” or “the Company”), today announced its results for the third quarter ended September 30, 2021. All figures included in this document are expressed in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS).

The following tables present an abbreviated income statement, in millions of Mexican pesos. The margin of each figure represents its ratio to sales and the percentage change for the third quarter of 2021 compared to the same period in 2020:


Q3 2021

% Sales

Q3 2020

% Sales

Var.%

Net sales

3 983.9

100.0%

3427.9

100.0%

16.2%

Gross profit

2 454.9

61.6%

2 189.9

63.9%

12.1%

Operating result

783.5

19.7%

731.7

21.3%

7.1%

EBITDA(1)

819.0

20.6%

769.4

22.4%

6.5%

Net revenue

393.2

9.9%

409.1

11.9%

(3.9%)


1) EBITDA defined as operating income before depreciation

Strong points

  • Q3-2021 Sales increased by Ps. 556.0 million; + 16.2% over one year.
  • Q3-2021 EBITDA closed at Ps. 819.0 million; + 6.5% over one year.
  • Ps. 1.76 billion in cash and cash equivalents September 30, 2021.
  • Net debt to Q3-2021 EBITDA ratio of 1.49x.
  • The company received Good Manufacturing Practices (GMP) certification during 3Q-2021.
  • 12th consecutive quarter of revenue growth.
  • Record EBITDA in absolute terms.

For a full version of Genomma Lab’s third quarter 2021 results release, please visit: https://inversionistas.genommalab.com/en/financial-information

CONFERENCE INFORMATION:

Genomma Lab will host a conference call on Thursday, October 28, 2021 discuss these results at 11:00 am Eastern Time / 10:00 central hour (Mexico time).

To access the call, please dial:
+1 877-407-0784 (From the United States)
+1 201-689-8560 (from outside the United States)

If you would rather receive a call than log in, please register via the following link. Please use this option 10 to 15 minutes before the conference call start time: Call Me Link

Participants who do not wish to be interrupted to have their information collected can request the provider to call them by clicking on the link above, filling out the information and pressing the green phone button at the bottom. The telephone number provided will be automatically called and connected to the conference without any interruption for the participant. (Please note: Participants will be directly joined to the conference and will hear music on hold until the call begins. No confirmation message will be played once joined.)

Webcast:
There will also be a live audio webcast of the event during Genomma’s third quarter 2021 earnings call.

Replay:
+1 844-512-2921 (US)
+1 412-317-6671 (International)
Replay ID: 13723981
Available until November 4, 2021

On
Genomma Lab Internacional, SAB de CV is one of the leading pharmaceutical and personal care companies in Mexico with a growing international presence. Genomma Lab develops, sells and markets a wide range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Genomma Lab is built on the combination of a successful new product development process, consumer-focused marketing, an extensive retail distribution network, and a low-cost, high-performance operating model. flexible.

Genomma Lab shares are listed on the Mexican Stock Exchange under the symbol “LAB B” (Bloomberg: LABB: MM).

Note on forward-looking statements
This report may contain certain forward-looking statements and information relating to the Company which reflect the current opinions and / or expectations of the Company and its management with regard to its performance, activities and future events. Forward-looking statements include, without limitation, any statement which may predict, predict, indicate or imply future results, performance or achievements, and may contain words such as “believe”, “anticipate”, “expect to “,” is considering “,” will likely result “, or any word or phrase with a similar meaning. These statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of material factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to rely on unduly to these forward-looking statements, which speak only as of their dates. Risks and uncertainties include, but are not limited to: risks related to the impact of the pandemic global level of COVID19, such as the extent and duration of the outbreak, government actions and restrictive measures implemented in response, significant delays, supply chain disruptions and other impacts to the business, or the Company’s ability to execute business continuity plans due to the COVID-19 pandemic, economic factors, such as fluctuations in interest rates and currency exchange rates; competition, including technological advances, new products obtained by competitors; the challenges inherent in the development of new products; the Company’s ability to successfully execute its strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; material adverse litigation or government action, including related to product liability claims; changes in applicable laws and regulations, including tax laws; changes in the behavior and spending habits of buyers of products and services; the financial instability of economies and international legal systems and sovereign risk. A list and additional descriptions of these risks, uncertainties and other factors can be found in the Company’s related documents with Bolsa Mexicana de Valores. Any forward-looking statements made in this press release speak only as of the date of this press release. The Company assumes no obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.

Contact details:
Investor Relations
Phone: +52 (55) 5081-0075
[email protected]

Barbara cano, InspIR Group
Phone. : +1 (646) 452-2334
[email protected]

SOURCE Genomma Lab Internacional, SAB de CV